VE-Cadherin Antibody (BV14) - BSA Free

Western Blot: VE-Cadherin Antibody (BV14)BSA Free [NBP1-43347]

Western Blot: VE-Cadherin Antibody (BV14) [NBP1-43347] - Non-reduced (left) and reduced (right) bEnd.3 cell line lysates were loaded at 1x10^5 cells/lane, probed with 2 ug/mL of Anti-Mouse CD144 (VE-Cadherin) Purified and revealed with Anti-Rat IgG HRP.

Western Blot: VE-Cadherin Antibody (BV14) - BSA Free [NBP1-43347] -

MAP4K4 deficiency induces TGF beta/smad signaling and EndMT via activation of integrin beta1. (a) HMVECs were transfected with MAP4K4 siRNA (100 nM) for 48 h. Next, the cells were treated with or without AcSDKP for 2 h. The p-smad3/smad3 pathway was analyzed by western blot. Densitometric analysis of the p-smad3/smad3 levels was performed, with n=3 for each group. (b) HMVECs were treated with MAP4K4 siRNA for 48 h with or without AcSDKP treatment. The VE-cadherin, CD31, FSP1, SM22 alpha and vimentin protein levels were analyzed by western blot. (c) HMVECs were transfected with MAP4K4 siRNA for 48 h in the presence or absence of TGF beta2 with or without AcSDKP. The integrin beta1 level was analyzed by western blot Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28771231), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: VE-Cadherin Antibody (BV14) - BSA Free [NBP1-43347] -

AcSDKP suppresses TGF beta/smad signaling and EndMT through the FGFR1/FRS2 pathway. (a) HMVECs were treated with N-FGFR1 for 48 h, and the FGFR1, TGF betaR1 and TGF betaR2 protein levels were analyzed by western blot. (b) HMVECs were treated with TGF beta2 in the presence or absence of N-FGFR1 for 15 min with or without AcSDKP preincubation. The p-smad3 and TGF betaR1 protein levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3 and TGF betaR1/ beta-actin levels (n=3) in each group was performed. (c) HMVECs were incubated with either N-FGFR1 in the presence or absence of TGF beta2 for 48 h with or without preincubation with AcSDKP for 2 h or with N-FGFR1 in the presence or absence of TGF beta2 for 48 h with or without 24 h of incubation with FGF2 (50 ng/ml). The CD31, SM22 alpha, FSP1 and alpha-SMA protein levels were analyzed by western blot. (d) HMVECs were transfected with FRS2 siRNA (100 nM) for 48 h with or without AcSDKP preincubation. The VE-cadherin, FSP1, vimentin, SM22 alpha and p-smad3 levels were analyzed by western blot. (e) HMVECs were treated with N-FGFR1 for 48 h or 15 min in the presence or absence of N-TGF beta (1, 2, 3) (1.0 μg/ml). The CD31, VE-cadherin, SM22 alpha, FSP1, TGF betaR1, TGF betaR2 and p-smad3 levels were analyzed by western blot Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28771231), licensed under a CC-BY license. Not internally tested by Novus Biologicals.